Tuesday, January 11, 2011

Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016

Pulmonary Arterial Hypertension (PAH) – Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Pulmonary Arterial Hypertension (PAH) – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global PAH market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global PAH market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global PAH sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
Scope
The scope of the report includes:
  • Annualized global PAH market revenues data from 2005 to 2009, forecast forward for seven years to 2016.
  • Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include endothelin receptor antagonists, platelet aggregation inhibitors, phosphodiesterase inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, P2Y 12 receptor inhibitors, PDE5 inhibitors, prostacyclin (PGI2) agonists, nitric oxide synthetase inhibitors.
  • Analysis of the current and future market competition in the global PAH market. Key market players covered are Actelion Ltd.,United Therapeutics Corporation, Bayer AG, Gilead Sciences, Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Lung RX and GlaxoSmithKline Plc.
  • Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with PAH.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global PAH market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global PAH market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global PAH market landscape? – Identify, understand and capitalize.
Buy Now: Market Research

Related Reports

at